Search results for "GLUCOCORTICOIDS"

showing 10 items of 162 documents

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

2012

BACKGROUND: Some patients with severe asthma have recurrent asthma exacerbations associated with eosinophilic airway inflammation. Early studies suggest that inhibition of eosinophilic airway inflammation with mepolizumab-a monoclonal antibody against interleukin 5-is associated with a reduced risk of exacerbations. We aimed to establish efficacy, safety, and patient characteristics associated with the response to mepolizumab. METHODS: We undertook a multicentre, double-blind, placebo-controlled trial at 81 centres in 13 countries between Nov 9, 2009, and Dec 5, 2011. Eligible patients were aged 12-74 years, had a history of recurrent severe asthma exacerbations, and had signs of eosinophil…

AdultMalemedicine.medical_specialtyAdolescentPlacebo-controlled studyFevipiprantAntibodies Monoclonal HumanizedPlaceboLebrikizumabDrug Administration ScheduleLeukocyte CountYoung Adultchemistry.chemical_compoundDouble-Blind MethodReslizumabInternal medicineSecondary PreventionmedicineHumansAnti-Asthmatic AgentsPulmonary EosinophiliaChildGlucocorticoidsAgedAsthmaDose-Response Relationship Drugbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseBenralizumabAsthmaEosinophilsTreatment OutcomechemistryPhysical therapyDrug Therapy CombinationFemaleInterleukin-5businessMepolizumabmedicine.drugThe Lancet
researchProduct

Treatment and its side effects in ANCA-associated vasculitides - Study based on POLVAS registry data.

2020

Abstract Purpose The aim of this study is to present the treatment modalities and associated side effects in a Polish nation-wide ANCA-associated vasculitides (AAV) patients’ cohort. Materials and methods Retrospective analysis of patients diagnosed with AAV between 1990 and 2016, included in the POLVAS registry was performed. Standard descriptive statistic methods were used with an emphasis on the treatment modalities. Results There were 625 patients diagnosed with AAV included in this study: 417 cases of granulomatosis with polyangiitis (GPA; 66.7%), 106 cases of microscopic polyangiitis (MPA; 17.0%) and 102 cases of eosinophilic granulomatosis with polyangiitis (EGPA; 16.3%). The mean ag…

AdultMalemedicine.medical_specialtyCyclophosphamideDrug-Related Side Effects and Adverse ReactionsAzathioprineAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis03 medical and health sciences0302 clinical medicineMaintenance therapyInternal medicineAzathioprinemedicineHumansTreatment complications030212 general & internal medicineRegistriesAdverse effectCyclophosphamideGlucocorticoidsANCA associated vasculitisRetrospective Studiesbusiness.industryVasculitis registryGeneral MedicineMiddle Agedmedicine.diseasePrognosisSurvival RateMethotrexate030220 oncology & carcinogenesisCohortRituximabDrug Therapy CombinationFemalePolandMicroscopic polyangiitisGranulomatosis with polyangiitisbusinessRituximabVasculitis treatmentImmunosuppressive Agentsmedicine.drugFollow-Up StudiesAdvances in medical sciences
researchProduct

Immunosuppressive treatment in bilateral vestibulopathy with inner ear antibodies.

2005

Although vestibular recovery was observed after steroid treatment, it remains uncertain whether this improvement was spontaneous or due to medication. These data do not allow us to generally recommend corticosteroid treatment in patients with BVF and inner ear antibodies.A retrospective study was performed based on the observation of two patients with suspected autoimmune bilateral vestibular failure (BVF) with normal hearing and antilabyrinthine or nervous tissue-specific serum antibodies who showed vestibular recovery after corticosteroid treatment.Twelve patients with BVF and serum inner ear antibodies who had received imuunosuppressive treatment with corticosteroids were evaluated in te…

AdultMalemedicine.medical_specialtyFluorescent Antibody TechniqueEar diseaseMethylprednisoloneNystagmus PathologicAutoimmune Diseasesotorhinolaryngologic diseasesmedicineCaloric TestsAnimalsHumansMedical historyInner earGlucocorticoidsAgedAutoantibodiesRetrospective StudiesVestibular systemmedicine.diagnostic_testbusiness.industryElectronystagmographyAutoimmune inner ear diseaseGeneral MedicineReflex Vestibulo-OcularMiddle Agedmedicine.diseaseBilateral vestibulopathySurgeryRatsmedicine.anatomical_structureTreatment OutcomeOtorhinolaryngologyElectronystagmographyVestibular DiseasesAnesthesiaEar InnerImmunoglobulin GFemalesense organsVestibulo–ocular reflexbusinessFollow-Up StudiesActa oto-laryngologica
researchProduct

Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study.

2021

OBJECTIVE To describe the efficacy and safety of biologics for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA). METHODS A retrospective European collaborative study was conducted in patients with EGPA who received treatment with biologics for refractory and/or relapsing disease. RESULTS Among the 147 patients with EGPA included in the study, 63 received rituximab (RTX), 51 received mepolizumab (MEPO), and 33 received omalizumab (OMA). At the time of inclusion, the median Birmingham Vasculitis Activity Score (BVAS) was 8.5 (interquartile range [IQR] 5-13) in the RTX group, while the median BVAS in the OMA group was 2 (IQR 1-4.5) and the median BVAS in the MEPO group was…

AdultMalemedicine.medical_specialtyImmunologyBirmingham Vasculitis Activity ScoreOmalizumabOmalizumabChurg-Strauss SyndromeAntibodies Monoclonal Humanized03 medical and health sciences0302 clinical medicineRheumatologyInterquartile rangeRecurrenceInternal medicinemedicineImmunology and AllergyHumansImmunologic Factors030212 general & internal medicineTreatment FailureAdverse effectGlucocorticoidsAgedRetrospective Studies030203 arthritis & rheumatologyBiological Productsbusiness.industryMiddle Agedmedicine.diseaseAsthmaTreatment OutcomeRituximabFemaleVasculitisbusinessGranulomatosis with polyangiitisRituximabMepolizumabmedicine.drugArthritisrheumatology (Hoboken, N.J.)References
researchProduct

Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study.

2000

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) of unknown etiology frequently requiring long-term therapy for control of symptoms and prevention of relapse. Azathioprine (AZA) has been shown to be effective and safe in the treatment of chronic active UC. However, the alternatives to treatment with AZA are limited. Our aim was to compare the efficacy and safety of treatment with mycophenolate mofetil (MMF)/prednisolone versus standard immunosuppressive treatment with azathioprine (AZA)/prednisolone in patients with chronic active UC.The study was designed as an open comparison of MMF versus AZA. Twenty-four patients with active UC (Rachmilewitz scoreor =6 points) were randoml…

AdultMalemedicine.medical_specialtyRandomizationPrednisoloneAzathioprinePilot ProjectsMycophenolateGastroenterologyMycophenolic acidInternal medicineAzathioprineMedicineHumansColitisGlucocorticoidsAgedHepatologybusiness.industryChronic ActiveRemission InductionGastroenterologyMiddle AgedMycophenolic Acidmedicine.diseaseUlcerative colitisSurgeryChronic DiseasePrednisoloneColitis UlcerativeDrug Therapy CombinationFemalebusinessImmunosuppressive Agentsmedicine.drugThe American journal of gastroenterology
researchProduct

A new delivery system of clobetasol-17-propionate (lipid-loaded microspheres 0.025%) compared with a conventional formulation (lipophilic ointment in…

2004

Summary Background  Topical application of clobetasol-17-propionate has been diffusely reported as an efficacious therapy in atrophic/erosive oral lichen planus (OLP), without exposing the patient to systemic side-effects. However, prolonged contact and respective topical effects on the oral mucosa should be avoided. Objectives  The aim of the present study was to evaluate efficacy and compliance of new lipid microspheres loaded with 0·025% of clobetasol propionate (formulation A) compared with a commonly used formulation (a sort of dispersion of a lipophilic ointment in a hydrophilic phase) with the same amount of drug (formulation B) in the topical treatment of OLP. Patients and methods  …

AdultMalemedicine.medical_specialtyRandomizationVisual analogue scaleAdministration TopicalChemistry PharmaceuticalAnti-Inflammatory AgentsDermatologyDosage formlaw.inventionOintmentsDrug Delivery SystemsRandomized controlled triallawMedicineHumansSingle-Blind MethodOral mucosaGlucocorticoidsAgedAged 80 and overClobetasolbusiness.industryMiddle Agedmedicine.diseaseDermatologyLipidsMicrospheresRegimenmedicine.anatomical_structureclobetasol propionate delivery lipid microspheres oral lichen planusPatient ComplianceOral lichen planusFemaleClobetasol propionatebusinessmedicine.drugLichen Planus OralThe British journal of dermatology
researchProduct

Beclomethasone dipropionate in Crohn's ileitis: A randomised, double-blind trial.

2011

Abstract Background Steroids, the mainstay of Crohn's disease treatment, have been associated with systemic side effects. Aim To evaluate the efficacy and tolerability of beclomethasone dipropionate for maintaining remission induced by a short course of systemic steroids in patients with Crohn's ileitis with or without right colonic involvement. Methods Patients (n = 84) with active Crohn's disease who achieved remission during a 2-week prednisone run-in period were randomised to receive beclomethasone dipropionate for 24 weeks or continue prednisone for a further 2 weeks followed by placebo for 22 weeks. The primary outcome was relapse rate (Crohn's Disease Activity Index score > 150 and a…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaRemissionKaplan-Meier EstimateBeclomethasone dipropionate Crohn's disease RemissionPlaceboGastroenterologyDrug Administration ScheduleMedication Adherencelaw.inventionDouble blindCrohn DiseaseDouble-Blind MethodRandomized controlled triallawPrednisoneInternal medicineSecondary PreventionmedicineHumansIleitisAdverse effectGlucocorticoidsAgedCrohn's diseaseHepatologybusiness.industryRemission InductionBeclomethasoneGastroenterologyBeclomethasone dipropionate Crohn's ileitis:.Middle Agedmedicine.diseaseSurgeryBeclomethasone dipropionateCrohn's diseaseTreatment OutcomeTolerabilityPrednisoneFemaleTablets Enteric-Coatedbusinessmedicine.drug
researchProduct

Influence of perioperative dexamethasone on delayed union in mandibular fractures: a clinical and radiological study

2014

Background: The aim was to clarify the occurrence of delayed union after surgical treatment of mandibular fracture and investigate whether an association exists between perioperative use of dexamethasone and delayed union. Material and Methods: Thirty-seven patients were included in a prospective randomized study. Of these patients, 19 (51.4%) were randomized to receive a total dose of 30 mg of dexamethasone and 18 (48.6%) served as controls. Patients underwent clinical and radiological investigation immediately, one month, three months and six months postoperatively. Radiographs were evaluated by an experienced, blinded senior oral radiologist. Results: Delayed fracture union was found in …

AdultMalemedicine.medical_specialtyTime FactorsAdolescentMandibular fractureOdontologíaBone healingDexamethasonelaw.inventionYoung AdultRandomized controlled triallawMandibular FracturesmedicineHumansProspective StudiesYoung adultProspective cohort studyGeneral DentistryGlucocorticoidsDexamethasoneFracture Healingbusiness.industryResearchPerioperativeMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludSurgeryRadiographyOtorhinolaryngologyConcomitantUNESCO::CIENCIAS MÉDICASSurgeryFemaleOral Surgerybusinessmedicine.drug
researchProduct

Intratympanic Dexamethasone/Hyaluronic Acid Mix as an Adjunct to Intravenous Steroid and Vasoactive Treatment in Patients With Severe Idiopathic Sudd…

2011

To evaluate differences in effectiveness (hearing recovery rates) between idiopathic sudden sensorineural hearing loss (ISSNHL) patients treated with intravenous therapy alone and patients treated with a combination of intravenous and intratympanic therapy.Retrospective case review.Tertiary referral hospital center.Ninety-four patients with moderate ISSNHL treated with an intravenous steroid and vasoactive regimen (duration of therapy, 9 ± 2.76 d) and 76 patients with severe ISSNHL treated with a combination regimen of intravenous and intratympanic therapy (duration of therapy, 10 ± 2.71 d) were reviewed. In the latter patients' group, a series of 3 intratympanic injections of a dexamethaso…

AdultMalemedicine.medical_specialtyTympanic MembraneHearing Loss Sensorineuralmedicine.medical_treatmentIntratympanic dexamethasoneDexamethasoneInjectionsSteroidchemistry.chemical_compoundVasoactiveInternal medicineHyaluronic acidotorhinolaryngologic diseasesmedicineHumansIn patientHyaluronic AcidGlucocorticoidsRetrospective Studiesbusiness.industryHearing Loss SuddenSensory SystemsHearing recoveryTreatment OutcomeEndocrinologyOtorhinolaryngologychemistryIntravenous therapyAnesthesiaSudden sensorineural hearing lossInjections IntravenousAudiometry Pure-ToneFemaleSteroidsNeurology (clinical)businessOtology & Neurotology
researchProduct

Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients.

2011

To evaluate adalimumab therapy in refractory uveitis.Prospective case series.A total of 131 patients with refractory uveitis and intolerance or failure to respond to prednisone and at least 1 other systemic immunosuppressive drug participated.Patients received a 40 mg adalimumab subcutaneous injection every other week for 6 months. The associated immunosuppressants were tapered after administering 3 adalimumab injections (week 6).Degree of anterior and posterior chamber inflammation (Standardization of Uveitis Nomenclature Working Group criteria), immunosuppression load (as defined by Nussenblatt et al), visual acuity (logarithm of the minimal angle of resolution [logMAR]), and macular thic…

AdultMalemedicine.medical_specialtyVisual acuityAdolescentInjections SubcutaneousAnti-Inflammatory AgentsDrug ResistanceVisual AcuityArthritisAntibodies Monoclonal HumanizedUveitisRefractoryPrednisoneInternal medicineAdalimumabMedicineHumansMacula LuteaProspective StudiesPars PlanitisProspective cohort studyChildGlucocorticoidsbusiness.industryTumor Necrosis Factor-alphaAdalimumabOff-Label Usemedicine.diseaseSurgeryOphthalmologyMethotrexateTreatment OutcomeChild PreschoolCyclosporineFemalemedicine.symptombusinessUveitisTomography Optical Coherencemedicine.drugOphthalmology
researchProduct